All In Biotech

Drug Trial Radar · NCT05669430

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

An Open-Label Phase 1/2A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Advanced and/or Refractory Solid Tumor Malignancies

Last checked: Nov 20, 2026Latest source record: Feb 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

365

Planned (sponsor's estimate)

Start

Mar 23, 2023

Primary completion

Dec 15, 2026

Study completion Sep 5, 2027

Sponsor

Lead sponsor
GV20 TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Dec 30, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.

Conditions

  • Solid Tumor, Adult
  • Refractory Cancer
  • Endometrial Carcinoma (EC)
  • Squamous Head and Neck Carcinoma
  • pMMR/MSS Adenocarcinoma of the Colon or Rectum
  • Cutaneous Melanoma
  • Non-Small Cell Lung Cancer

Interventions

  • GV20-0251Biological

    Increasing doses of GV20-0251 administered by intravenous (IV) infusion once or twice every 3 weeks as monotherapy.

  • GV20-0251Biological

    GV20-0251 preliminary RP2D administered by IV infusion as monotherapy.

  • GV20-0251 and Pembrolizumab [KEYTRUDA®]Biological

    GV20-0251 administered by IV infusion at 10 mg/kg once every 3 weeks or at increasing doses up to the preliminary RP2D determined in Part A. 200 mg pembrolizumab administered by IV infusion once every 3 weeks.

  • GV20-0251 and Pembrolizumab [KEYTRUDA®]Biological

    GV20-0251 administered by IV infusion at preliminary RP2D from Part C. 200 mg pembrolizumab administered by IV infusion once every 3 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate ORR per RECIST version 1.1 (Parts B and D)Time frame: 12 months
  2. Percentage of Participants With Adverse Events (Parts A and C)Time frame: 12 months

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • The Angeles Clinic and Research Institute

    Los Angeles, California · Recruiting

  • HealthONE Clinic Services Oncology - Hematology, LLC d/b/a Sarah Cannon Research Institute at HealthONE

    Denver, Colorado · Not yet recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

  • Florida Cancer Specialists & Research Institute, LLC

    Fort Myers, Florida · Not yet recruiting

  • Community Health Network, Inc.

    Indianapolis, Indiana · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center

    Detroit, Michigan · Recruiting

  • NYU Langone Health

    New York, New York · Recruiting

  • Oregon Health & Science University

    Portland, Oregon · Recruiting

  • Verdi Oncology Tennessee, Scri Oncology Partners

    Nashville, Tennessee · Not yet recruiting

  • Oncology Consultants, P.A.

    Houston, Texas · Recruiting

  • The University of Texas M. D. Anderson Cancer Center

    Houston, Texas · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.